Stocklytics Platform
Asset logo for symbol CYTK
Cytokinetics
CYTK49
$50.70arrow_drop_up0.31%$0.16
Asset logo for symbol CYTK
CYTK49

$50.70

arrow_drop_up0.31%

Performance History

Chart placeholder
Key Stats
Open$50.42
Prev. Close$50.55
EPS-5.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range49.80
51.00
52 Week Range30.10
110.25
Ratios
EPS-5.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Cytokinetics (CYTK)

Cytokinetics Inc (CYTK) is a biopharmaceutical company focused on the discovery and development of novel muscle biology therapies. The company is committed to improving the lives of patients with debilitating muscle diseases by developing treatments that address the underlying cause of these conditions. With a strong pipeline and a strategic focus on precision medicine, Cytokinetics is well-positioned for future growth in the biotechnology industry.
Cytokinetics' stock price history has shown resilience and steady growth over the years. Despite facing challenges in the highly competitive biopharmaceutical market, the company has managed to maintain a positive trajectory. Investors have been attracted to Cytokinetics' innovative approach to muscle biology and its potential to revolutionize the treatment of various disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert I. Blum
Headquarters
South San Francisco
Employees
409
Exchange
NASDAQ
add Cytokinetics  to watchlist

Keep an eye on Cytokinetics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Cytokinetics 's (CYTK) price per share?

The current price per share for Cytokinetics (CYTK) is $50.7. The stock has seen a price change of $0.16 recently, indicating a 0.32% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Cytokinetics (CYTK)?

For Cytokinetics (CYTK), the 52-week high is $110.25, which is 117.46% from the current price. The 52-week low is $30.1, the current price is 68.44% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Cytokinetics (CYTK) a growth stock?

Cytokinetics (CYTK) has shown an average price growth of -1.97% over the past three years. It has received a score of 67 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cytokinetics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Cytokinetics (CYTK) stock price performance year to date (YTD)?

As of the latest data, Cytokinetics (CYTK) has a year-to-date price change of -39.73%. Over the past month, the stock has experienced a price change of -13.51%. Over the last three months, the change has been -9.19%. Over the past six months, the figure is -6.39%. Looking at a longer horizon, the five-year price change stands at 426.48%.
help

Is Cytokinetics (CYTK) a profitable company?

Cytokinetics (CYTK) has a net income of -$526.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -30.41K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $7.53M, although specific revenue growth data is currently not available. Operating income is noted at -$496.2M. Furthermore, the EBITDA is -$511.14M.
help

What is the market capitalization of Cytokinetics (CYTK)?

Cytokinetics (CYTK) has a market capitalization of $5.98B. The average daily trading volume is 50.55, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level